Main menu

Catalent Acquires US Commercial Cell Therapy Facility

Establishing US-based campus to support late-stage and commercial manufacturing for autologous and allogeneic cell therapies

Catalent Invests $350 Million at Bloomington, Indiana Site

Expanding Biomanufacturing and Fill/Finish Capabilities

Catalent is the #1 partner in helping pharmaceutical, biotech and consumer health innovators develop, deliver and supply superior products that improve people’s lives.

Catalent acquires US Commercial Cell Therapy Facility

Establishing US-based campus to support late-stage and commercial manufacturing for autologous and allogeneic cell therapies

Catalent Invests $350 Million at Bloomington, Indiana Site

Expanding Biomanufacturing and Fill/Finish Capabilities

Catalent is the #1 partner in helping pharmaceutical, biotech and consumer health innovators develop, deliver and supply superior products that improve people’s lives.